[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ID23372A - Pengobatan diabetes dengan tiazolidindion dan metformin - Google Patents

Pengobatan diabetes dengan tiazolidindion dan metformin

Info

Publication number
ID23372A
ID23372A IDW991629A ID991629A ID23372A ID 23372 A ID23372 A ID 23372A ID W991629 A IDW991629 A ID W991629A ID 991629 A ID991629 A ID 991629A ID 23372 A ID23372 A ID 23372A
Authority
ID
Indonesia
Prior art keywords
tiazolidindion
metformin
diabetes
treatment
Prior art date
Application number
IDW991629A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID23372(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ID23372A publication Critical patent/ID23372A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW991629A 1997-06-18 1998-06-15 Pengobatan diabetes dengan tiazolidindion dan metformin ID23372A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
ID23372A true ID23372A (id) 2000-04-20

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991629A ID23372A (id) 1997-06-18 1998-06-15 Pengobatan diabetes dengan tiazolidindion dan metformin

Country Status (39)

Country Link
US (3) US20060100247A1 (id)
EP (2) EP1787646A3 (id)
JP (1) JP2002504137A (id)
KR (2) KR100666591B1 (id)
CN (2) CN1230171C (id)
AP (1) AP1279A (id)
AR (2) AR012995A1 (id)
AT (1) ATE355840T1 (id)
AU (1) AU8539398A (id)
BG (2) BG109398A (id)
BR (1) BR9810172A (id)
CA (1) CA2294582C (id)
CY (2) CY1107643T1 (id)
CZ (1) CZ298469B6 (id)
DE (2) DE122007000054I1 (id)
DK (1) DK0996444T3 (id)
DZ (1) DZ2520A1 (id)
EA (1) EA003144B1 (id)
ES (1) ES2284212T3 (id)
HK (1) HK1028193A1 (id)
ID (1) ID23372A (id)
IL (3) IL133142A0 (id)
IN (1) IN189722B (id)
LU (1) LU91356I2 (id)
MA (1) MA26512A1 (id)
MY (1) MY129897A (id)
NL (1) NL300288I2 (id)
NO (4) NO324993B1 (id)
NZ (1) NZ501260A (id)
OA (1) OA11516A (id)
PE (1) PE83199A1 (id)
PL (2) PL195140B1 (id)
PT (1) PT996444E (id)
SI (1) SI0996444T1 (id)
SK (1) SK286029B6 (id)
TR (1) TR199903057T2 (id)
TW (1) TW565449B (id)
UY (1) UY25049A1 (id)
WO (1) WO1998057634A1 (id)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2180296C (en) * 1995-07-03 2007-01-09 Yoshio Tsujita Treatment of arteriosclerosis and xanthoma
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
EP0974356B1 (en) * 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
AU3960400A (en) * 1999-03-05 2000-09-28 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AR023564A1 (es) 1999-04-23 2002-09-04 Smithkline Beecham Plc Una forma polimorfica de sal del acido maleico derivado del tiazolidina-2,4 diona, una composicion farmaceutica y el uso del mismo para la fabricacion deun medicamento
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
IL149139A0 (en) 1999-11-03 2002-11-10 Bristol Myers Squibb Co Pharmaceutical compositions containing metformin and glyburide
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
ES2290130T3 (es) * 2000-05-01 2008-02-16 Aeropharm Technology, Llc Formulacion de nucleo.
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
ATE508738T1 (de) 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
CA2499597C (en) * 2002-09-20 2012-01-17 Unchalee Kositprapa Multistage formulation containing a biguanide and thiazolidindione derivatives
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1588708A4 (en) 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
WO2006011397A1 (ja) * 2004-07-27 2006-02-02 Kowa Company., Ltd. 糖尿病の予防または治療のための薬剤
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
CN101272805A (zh) * 2005-07-12 2008-09-24 第一三共株式会社 包含PPARγ激动剂的药物组合物
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
JP2012503595A (ja) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
KR102231554B1 (ko) 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
ES2161291T3 (es) * 1995-06-06 2001-12-01 Pfizer N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
DE69822505T2 (de) * 1997-12-08 2005-01-20 Bristol-Myers Squibb Co. Neue metformin-salze und verfahren
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
EP0996444A1 (en) 2000-05-03
HK1028193A1 (en) 2001-02-09
CY1107643T1 (el) 2012-01-25
AU8539398A (en) 1999-01-04
KR100666591B1 (ko) 2007-01-11
US20070004780A1 (en) 2007-01-04
NO996266L (no) 1999-12-17
BR9810172A (pt) 2000-08-08
SK179299A3 (en) 2000-11-07
ES2284212T3 (es) 2007-11-01
CZ9904578A3 (en) 2001-06-13
AP9901719A0 (en) 1999-12-31
IN189722B (id) 2003-04-19
BG64818B1 (bg) 2006-05-31
LU91356I2 (fr) 2008-01-29
KR20010013844A (ko) 2001-02-26
NO20063000L (no) 1999-12-17
PT996444E (pt) 2007-06-08
PL195136B1 (pl) 2007-08-31
DK0996444T3 (da) 2007-07-02
PL195140B1 (pl) 2007-08-31
JP2002504137A (ja) 2002-02-05
PE83199A1 (es) 1999-10-22
NL300288I1 (nl) 2007-11-01
EP0996444B1 (en) 2007-03-07
NO20090846L (no) 1999-12-17
EP1787646A3 (en) 2007-10-03
CZ298469B6 (cs) 2007-10-10
NL300288I2 (nl) 2009-06-02
TW565449B (en) 2003-12-11
NO996266D0 (no) 1999-12-17
US20060100247A1 (en) 2006-05-11
IL133142A (en) 2006-06-11
MA26512A1 (fr) 2004-12-20
NO2008003I2 (no) 2010-06-28
WO1998057634A1 (en) 1998-12-23
CN1230171C (zh) 2005-12-07
IL173650A0 (en) 2006-07-05
AP1279A (en) 2004-05-20
SI0996444T1 (sl) 2007-08-31
CY2007018I1 (el) 2012-01-25
PL337362A1 (en) 2000-08-14
TR199903057T2 (xx) 2000-04-21
SK286029B6 (sk) 2008-01-07
DE69837261T2 (de) 2007-11-08
KR20060105005A (ko) 2006-10-09
US20080090881A1 (en) 2008-04-17
BG109398A (bg) 2006-05-31
NZ501260A (en) 2002-09-27
CN1260716A (zh) 2000-07-19
CA2294582A1 (en) 1998-12-23
DZ2520A1 (fr) 2003-02-01
OA11516A (en) 2004-02-04
NO2008003I1 (no) 2008-04-21
CA2294582C (en) 2008-02-12
CN1114404C (zh) 2003-07-16
AR012998A1 (es) 2000-11-22
AR012995A1 (es) 2000-11-22
UY25049A1 (es) 2000-09-29
IL133142A0 (en) 2001-03-19
CN1429551A (zh) 2003-07-16
ATE355840T1 (de) 2007-03-15
EA003144B1 (ru) 2003-02-27
MY129897A (en) 2007-05-31
NO324993B1 (no) 2008-01-14
BG104060A (en) 2000-10-31
DE69837261D1 (de) 2007-04-19
DE122007000054I1 (de) 2007-12-13
NO326958B1 (no) 2009-03-23
EA200000041A1 (ru) 2000-08-28
EP1787646A2 (en) 2007-05-23

Similar Documents

Publication Publication Date Title
ID23372A (id) Pengobatan diabetes dengan tiazolidindion dan metformin
ID25504A (id) Pencegahan dan pengobatan penyakit amiloidogenik
ID24839A (id) Senyawa-senyawa triazol dan penggunaannya
ID20463A (id) Turunan-turunan penil-dan aminofenil-alkilsulfonamida dan urea
ID28114A (id) Sitokin mamalia; interleukin-b30 dan pereaksi-pereaksi terkait
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
ID24211A (id) Pengobatan penyakit gula dengan thiazolidindion, insulin sekretatagogue dan diguanida
ID23951A (id) Pengobatan diabetes dengan rosiglitazon dan insulin
ID19147A (id) Ksilanase dan pemakaiannya
ID24065A (id) Pengobatan diabetes dengan tiozolidindinon dan sulfonilurea
ATE366577T1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
PL337577A1 (en) Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor
ID18913A (id) Turunan turunan tienopiridin dan penggunaannya
FI960811A (fi) Yhdistetty katalysaattori ja äänenvaimennin
ID24941A (id) Antigen virus dengue dan pengobatan demam dengue
DE69803634D1 (de) Herstellung von Phenol und dessen Derivaten
HUP0002668A3 (en) Treatment of diabetes with thiazolidinedione and metformin
ID24355A (id) Pengobatan diabetes mellitus dengan tiazolidinadion dan inhibitor alfa-glukosidase
ID17395A (id) Aluminosilikat berbentuk beraturan dan penggunaannya
ID20518A (id) Turunan-turunan oksazolon dan penggunaannya
ID18287A (id) Fosforilamida, pembuatan dan penggunaannya
ID19017A (id) Turunan-turunan spiro-piperidin dan pemakaiannya sabagai bahan-bahan terapeutik
IDP000021741A (id) Turunan-turunan n-(4-aril-tiazol-2-il)-sulfonamida dan pemakaiannya
ID19848A (id) Senyawa-senyawa 1-arilpirazol produksi dan penggunaannya